Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H32O3 |
Molecular Weight | 332.477 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)\C(C[C@]34C)=C/O
InChI
InChIKey=ICMWWNHDUZJFDW-DHODBPELSA-N
InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
Molecular Formula | C21H32O3 |
Molecular Weight | 332.477 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11440282Curator's Comment: Description was created based on several sources, includinghttp://medapharma.us/products/pi/Anadrol-50_PI.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11365560
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11440282
Curator's Comment: Description was created based on several sources, includinghttp://medapharma.us/products/pi/Anadrol-50_PI.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11365560
Oxymetholone (17beta-hydroxy-2-[hydroxymethylene]-17-methyl-5alpha-androstan-3-one) is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone. It has been approved by the US Food and Drug Administration for the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Drug interactions exist with cimetidine, paroxetine, and haloperidol, but are not expected with indinavir, ritonavir, clarithromycin, or itraconazole.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10217522
Curator's Comment: Known to be CNS active in rats. Human data not available.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01511a040
Curator's Comment: Ringold et al, 1959 (Syntex SA)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6539197 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANADROL-50 Approved UseAnadrol®-50 Tablets is indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Anadrol®-50 Tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids. Launch Date6.4540799E10 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
unlikely [IC50 206 uM] | ||||
unlikely [IC50 300 uM] | ||||
Page: 4.0 |
unlikely [IC50 383 uM] | |||
unlikely [IC50 67.5 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Androgen-induced hepatoma. | 1975 Feb 22 |
|
Characterization of spontaneous and chemically induced cardiac lesions in rodent model systems: the national toxicology program experience. | 2005 |
|
Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. | 2009 Apr |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. | 2012 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://medapharma.us/products/pi/Anadrol-50_PI.pdf
The recommended daily dose in children and adults is 1-5 mg/kg of body weight per day.
The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose
should be individualized. Response is not often immediate, and a minimum trial of three to
six months should be given. Following remission, some patients may be maintained without
the drug; others may be maintained on an established lower daily dosage. A continued
maintenance dose is usually necessary in patients with congenital aplastic anemia.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15953861
0.1 to 10 uM oxymetholone tested on normal CD34+ cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:27:46 UTC 2022
by
admin
on
Fri Dec 16 19:27:46 UTC 2022
|
Record UNII |
L76T0ZCA8K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
WIKIPEDIA |
Designer-drugs-Oxymetholone
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
WHO-VATC |
QA14AA05
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
LIVERTOX |
727
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
WHO-ATC |
A14AA05
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1200585
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
D010110
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
L76T0ZCA8K
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
3374
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
26198
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
78964-17-7
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
ALTERNATIVE | |||
|
7864
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
1487007
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
OXYMETHOLONE
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
C723
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
7813
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | RxNorm | ||
|
L76T0ZCA8K
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
2033
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
SUB09568MIG
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
5281034
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
1022
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
M8336
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | Merck Index | ||
|
DB06412
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
434-07-1
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
DTXSID5023794
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY | |||
|
207-098-6
Created by
admin on Fri Dec 16 19:27:46 UTC 2022 , Edited by admin on Fri Dec 16 19:27:46 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |